CD274 and urothelial carcinoma: Currently, there are five anti‐PD‐1/PD‐L1 ICB immunotherapeutic drugs approved by the FDA for the treatment of bladder and other urothelial carcinomas (UCs), including three anti‐PD‐L1 and two anti‐PD‐1 antibodies 59 (Table 1).